Daily Morning Note – 30 November 2021


Asian stocks look set for a steady start after U.S. shares rebounded amid easing concerns about the impact of omicron on the global reopening. Futures for Japan and Australia rose while Hong Kong’s slipped. The S&P 500 wiped out its November losses and the tech-heavy Nasdaq 100 more than recouped Friday’s rout. Ten-year U.S. Treasury yields rose to about 1.5% but are below pre-omicron levels. Crude oil pared a gain of as much as 7% from Friday’s rout, while Bitcoin traded above $58,000, maintaining its recent rally.



Yangzijiang Shipbuilding has proposed a spin-off and listing of the group’s investment segment via the transfer of existing investments to a newly incorporated company that will focus on asset management and direct investments. This will create 2 separate listed companies to pursue more targeted business strategies and accelerate growth, said the group in a bourse filing on Monday (Nov 29).

IHH Healthcare’s third-quarter net profit jumped 77 per cent to RM550 million (S$177.6 million) year on year amid a steady return of patients to hospitals and the continued provision of Covid-19 support services. For the 3 months ended Sept 30, revenue was up 26 per cent to RM4.4 billion while Ebitda increased 32 per cent to RM1.1 billion with stringent cost controls in place, said the group in a press statement on Monday (Nov 29).

Pine Capital has on Nov 26 received a notification of delisting from the Singapore Exchange (SGX), it said in a bourse filing late Monday (Nov 29). The company’s shares will be delisted after an exit offer is made to shareholders and holders of other classes of listed securities to be delisted. The company, however, said it intends to appeal the delisting notice as it has on Nov 22 entered into a non-binding term sheet with Genv Holdings for a subscription of new shares and the proposed acquisition of a new business.

BRC Asia has posted a full-year net profit of S$47 million, up 131 per cent from a year ago, on improved sales volume and higher steel prices. The group has proposed a final dividend of 4 cents per share and a special dividend of 4 cents per share. Including the interim dividend paid out earlier in the year, total dividend for FY2021 stands at 12 cents per share, representing around 61 per cent of earnings. For the 12 months ended Sept 30, revenue rose 91 per cent to S$1.2 billion mainly due to higher sales volume with the pick-up in construction activities, coupled with higher selling prices in tandem with increasing international steel prices, said the group in a bourse filing on Monday (Nov 29).

No Signboard has reported a net loss of S$6.4 million for the year ended Sept 30, narrowing from S$9.8 million a year ago. This translates to a net loss per share of 1.37 cents, compared with 2.13 cents a year ago. Still, total revenue tumbled 42 per cent year on year to S$7.9 million in FY2021 amid the prolonged pandemic. Since February 2020, the group’s topline has been impacted by the decline in a number of customers when Singapore implemented travel entry restrictions on short-term visitors.

LHN Group‘s net profit rose 16.9 per cent to S$28.9 million for the full-year ended Sept 30, 2021, despite a 9.9 per cent slip in revenue from a year ago. This was mainly due to an improvement in the profitability of its space optimisation business (industrial and Singapore co-living segment), facilities management business and logistics services business – along with lowered cost of sales and operating expenses, said the group in a press statement last Friday (Nov 26). It has proposed a final dividend of 1 Singapore cent for FY2021.


Jack Dorsey, the co-founder and chief executive officer of Twitter Inc, is stepping down, ceding the position to the company’s chief technology officer Parag Agrawal. The move is effective immediately, though Dorsey will stay on the board of the social media company until his term expires in 2022, Twitter said in a statement Monday (Nov 29).

Moderna Inc shares jumped 11 percent in US pre-market trading after the company said a new vaccine to fight the omicron strain of the coronavirus could be ready by early 2022 if required. The stock jumped 21 per cent during Friday’s global selloff amid concerns about the new variant, solidifying its position as the top performer on the S&P 500 in the year to date. The company mobilised hundreds of workers on Thanksgiving Day last Thursday in order to start work on Omicron, chief medical officer Paul Burton said at the weekend.

The Omicron variant of Covid-19 could slow the recovery of the US economy and labour market, and heighten uncertainty regarding inflation, Federal Reserve Chair Jerome Powell said in testimony released on Monday. Powell also acknowledged that the factors pushing US inflation higher will “linger well into next year.” The comments in testimony to be delivered to the Senate Banking Committee on Tuesday indicate the Fed chief is growing more concerned about the spike in inflation seen this year, which he has consistently said would be transitory.

Wall Street stocks jumped on Monday, winning back some of the prior session’s losses on hopes that vaccines and therapeutics will limit the impact of the latest Covid-19 variant. Major indices tumbled more than two per cent on Friday on worries the Omicron variant could derail the global economic recovery. But investors appeared less concerned on Monday as vaccine makers Pfizer and Johnson & Johnson signaled they were already working on a potential formula targeted at the new strain.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

Technical Pulse: Akeso Inc.

Recommended: Technical BUY; Analyst: Chua Wei Ren

Akeso Inc (HKEX: 9926) Technicals are showing a bullish return

Buy spot: 49.90 Stop loss: 40.00 Take profit 1: 62.50 Take profit: 70.50

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Daily Morning Note – November 26, 2021

Daily Morning Note – November 25,2021

Daily Morning Note – November 24, 2021

Visit www.stocksbnb.com to learn more!

Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb

Webinar Of The Week

Weekly Market Outlook: Alphabet Inc, iX Biopharma, Thai Beverage, SG Weekly

Date: 29 November 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com